8 Best Undervalued Growth Stocks At 52w High for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current equity market is characterized by sector rotation and heightened interest in companies demonstrating resilient growth and strong free cash flow. Our selection methodology leverages ValueSense’s proprietary intrinsic value ratings, focusing on stocks with robust financial metrics, attractive valuations, and sector diversity. Each pick is screened for quality, recent performance, and catalysts that may drive future returns, ensuring a balanced and opportunity-rich watchlist.
Featured Stock Analysis
Cencora (COR)
| Metric | Value |
|---|---|
| Market Cap | $65.5B |
| Quality Rating | 6.2 |
| Intrinsic Value | $361.5 |
| 1Y Return | 48.8% |
| Revenue | $316.7B |
| Free Cash Flow | $1,141.6M |
| Revenue Growth | 11.6% |
| FCF margin | 0.4% |
| Gross margin | 3.3% |
| ROIC | 16.0% |
| Total Debt to Equity | 372.9% |
Investment Thesis
Cencora, with a market cap of $65.5B, stands out in the healthcare distribution sector for its scale and operational efficiency. The company’s intrinsic value of $361.5 suggests significant upside relative to current market pricing. Over the past year, Cencora delivered a 48.8% return, supported by $316.7B in revenue and a solid ROIC of 16.0%. Its quality rating of 6.2 reflects stable fundamentals and prudent capital allocation.
Cencora’s modest revenue growth of 11.6% and free cash flow of $1,141.6M highlight its ability to generate cash even in a margin-constrained industry. The company’s gross margin of 3.3% is typical for distributors, but its scale and operational leverage help offset competitive pressures.
Key Catalysts
- Expansion in specialty pharmaceuticals distribution
- Strategic partnerships with healthcare providers
- Efficiency gains from technology integration
- Potential for margin improvement through cost controls
Risk Factors
- High total debt to equity 372.9% increases financial risk
- Low free cash flow margin 0.4% limits reinvestment flexibility
- Regulatory changes in drug pricing could impact profitability
Warner Bros. Discovery, Inc. (WBD)
| Metric | Value |
|---|---|
| Market Cap | $55.6B |
| Quality Rating | 6.1 |
| Intrinsic Value | $26.4 |
| 1Y Return | 176.1% |
| Revenue | $38.4B |
| Free Cash Flow | $4,065.0M |
| Revenue Growth | (3.7%) |
| FCF margin | 10.6% |
| Gross margin | 52.7% |
| ROIC | (12.3%) |
| Total Debt to Equity | 92.7% |
Investment Thesis
Warner Bros. Discovery, with a $55.6B market cap, is a major player in global media and entertainment. The company’s intrinsic value of $26.4 and a remarkable 1-year return of 176.1% underscore its turnaround potential. Despite a revenue decline of 3.7% to $38.4B, WBD’s free cash flow of $4,065.0M and a high gross margin of 52.7% signal strong operational efficiency.
The quality rating of 6.1 reflects a mixed profile: while WBD excels in content monetization and cost management, its ROIC is negative -12.3%, indicating ongoing restructuring challenges.
Key Catalysts
- Integration of streaming platforms and content libraries
- Cost synergies from recent mergers
- Growth in direct-to-consumer digital services
- International expansion opportunities
Risk Factors
- Elevated debt levels (total debt to equity: 92.7%)
- Negative revenue growth and ROIC
- Intense competition from other streaming giants
Cardinal Health, Inc. (CAH)
| Metric | Value |
|---|---|
| Market Cap | $45.4B |
| Quality Rating | 6.9 |
| Intrinsic Value | $208.8 |
| 1Y Return | 76.5% |
| Revenue | $234.3B |
| Free Cash Flow | $4,452.0M |
| Revenue Growth | 4.4% |
| FCF margin | 1.9% |
| Gross margin | 3.7% |
| ROIC | 47.4% |
| Total Debt to Equity | (330.7%) |
Investment Thesis
Cardinal Health, with a $45.4B market cap, is a leading healthcare services provider. The company’s intrinsic value of $208.8 and a 1-year return of 76.5% highlight its strong market positioning. Cardinal Health generated $234.3B in revenue, with a quality rating of 6.9 and a robust ROIC of 47.4%, indicating efficient capital deployment.
Revenue growth of 4.4% and free cash flow of $4,452.0M support ongoing investments in logistics and technology. The company’s gross margin of 3.7% is consistent with industry norms, while its negative total debt to equity -330.7% suggests a net cash position or accounting anomaly.
Key Catalysts
- Expansion in specialty logistics and supply chain solutions
- Investments in digital health platforms
- Strategic acquisitions to enhance service offerings
- Cost optimization initiatives
Risk Factors
- Margin pressure from competitive pricing
- Regulatory risks in healthcare reimbursement
- Potential volatility in pharmaceutical distribution
Fox Corporation (FOX)
| Metric | Value |
|---|---|
| Market Cap | $26.1B |
| Quality Rating | 7.2 |
| Intrinsic Value | $114.6 |
| 1Y Return | 50.7% |
| Revenue | $16.5B |
| Free Cash Flow | $2,907.0M |
| Revenue Growth | 14.9% |
| FCF margin | 17.6% |
| Gross margin | 64.5% |
| ROIC | 18.1% |
| Total Debt to Equity | 53.6% |
Investment Thesis
Fox Corporation, valued at $26.1B, is a prominent media conglomerate with a focus on news, sports, and entertainment. The company’s intrinsic value of $114.6 and a 1-year return of 50.7% reflect its ability to navigate industry disruptions. Fox’s $16.5B revenue, quality rating of 7.2, and ROIC of 18.1% indicate strong profitability and capital efficiency.
Revenue growth of 14.9% and a high free cash flow margin 17.6% position Fox for continued investment in content and digital platforms. The gross margin of 64.5% underscores its premium content strategy.
Key Catalysts
- Growth in digital streaming and sports broadcasting
- Expansion of advertising revenue streams
- Strategic content partnerships
- Continued investment in original programming
Risk Factors
- Regulatory scrutiny of media ownership
- Cyclical advertising market
- Competition from digital-first platforms
Mueller Industries, Inc. (MLI)
| Metric | Value |
|---|---|
| Market Cap | $11.6B |
| Quality Rating | 8.2 |
| Intrinsic Value | $125.0 |
| 1Y Return | 29.5% |
| Revenue | $4,139.7M |
| Free Cash Flow | $676.5M |
| Revenue Growth | 15.7% |
| FCF margin | 16.3% |
| Gross margin | 28.8% |
| ROIC | 38.9% |
| Total Debt to Equity | 0.9% |
Investment Thesis
Mueller Industries, with a market cap of $11.6B, is a diversified manufacturer in the industrial sector. The company’s intrinsic value of $125.0 and a quality rating of 8.2 highlight its operational excellence. Mueller posted a 1-year return of 29.5%, with $4,139.7M in revenue and a stellar ROIC of 38.9%.
Revenue growth of 15.7% and a free cash flow margin of 16.3% demonstrate strong demand for its products and efficient cost management. The gross margin of 28.8% is robust for the sector, and total debt to equity of 0.9% reflects a conservative balance sheet.
Key Catalysts
- Expansion in HVAC and plumbing markets
- Product innovation and sustainability initiatives
- Geographic diversification
- Strategic acquisitions
Risk Factors
- Exposure to commodity price volatility
- Cyclical demand in construction and manufacturing
- Competitive pressures from global suppliers
Abivax S.A. (ABVX)
| Metric | Value |
|---|---|
| Market Cap | $6,494.4M |
| Quality Rating | 6.1 |
| Intrinsic Value | $175.2 |
| 1Y Return | 892.4% |
| Revenue | €15.1M |
| Free Cash Flow | (€250.0M) |
| Revenue Growth | 125.1% |
| FCF margin | (1,651.6%) |
| Gross margin | 100.0% |
| ROIC | 2,318.7% |
| Total Debt to Equity | (204.4%) |
Investment Thesis
Abivax S.A., with a market cap of $6,494.4M, is a biotechnology firm focused on innovative therapies. The company’s intrinsic value of $175.2 and an extraordinary 1-year return of 892.4% highlight its breakthrough potential. Abivax reported €15.1M in revenue, with a quality rating of 6.1 and an exceptional ROIC of 2,318.7%.
Revenue growth of 125.1% and a gross margin of 100% reflect the impact of new product launches. However, the negative free cash flow margin -1,651.6% and total debt to equity -204.4% indicate aggressive investment in R&D and possible funding challenges.
Key Catalysts
- Clinical trial progress and regulatory approvals
- Expansion of product pipeline
- Strategic partnerships with pharma companies
- Entry into new therapeutic markets
Risk Factors
- High cash burn and negative free cash flow
- Regulatory and clinical development risks
- Dependence on successful commercialization
Supernus Pharmaceuticals, Inc. (SUPN)
| Metric | Value |
|---|---|
| Market Cap | $3,088.6M |
| Quality Rating | 6.2 |
| Intrinsic Value | $63.4 |
| 1Y Return | 61.8% |
| Revenue | $665.1M |
| Free Cash Flow | $185.9M |
| Revenue Growth | 5.5% |
| FCF margin | 27.9% |
| Gross margin | 82.3% |
| ROIC | 5.6% |
| Total Debt to Equity | 5.3% |
Investment Thesis
Supernus Pharmaceuticals, with a market cap of $3,088.6M, specializes in central nervous system therapies. The company’s intrinsic value of $63.4 and a 1-year return of 61.8% highlight its growth trajectory. Supernus generated $665.1M in revenue, with a quality rating of 6.2 and a ROIC of 5.6%.
Revenue growth of 5.5% and a free cash flow margin of 27.9% indicate strong cash generation. The gross margin of 82.3% is impressive, supporting continued investment in R&D and product launches.
Key Catalysts
- Expansion of CNS drug portfolio
- New product launches and patent extensions
- Growth in specialty pharma markets
- Strategic licensing agreements
Risk Factors
- Regulatory risks in drug approval
- Patent expirations
- Competition from generics
SOPHiA GENETICS SA (SOPH)
| Metric | Value |
|---|---|
| Market Cap | $336.6M |
| Quality Rating | 5.2 |
| Intrinsic Value | $8.3 |
| 1Y Return | 39.7% |
| Revenue | $69.7M |
| Free Cash Flow | ($43.6M) |
| Revenue Growth | 7.3% |
| FCF margin | (62.6%) |
| Gross margin | 67.8% |
| ROIC | (115.4%) |
| Total Debt to Equity | 83.2% |
Investment Thesis
SOPHiA GENETICS SA, with a market cap of $336.6M, is a data-driven healthcare company specializing in genomic analysis. The company’s intrinsic value of $8.3 and a 1-year return of 39.7% reflect its emerging growth profile. SOPHiA generated $69.7M in revenue, with a quality rating of 5.2 and a negative ROIC -115.4%.
Revenue growth of 7.3% and a gross margin of 67.8% highlight its scalable business model, though negative free cash flow -$43.6M and elevated debt levels 83.2% point to ongoing investment needs.
Key Catalysts
- Expansion of genomic data platforms
- Partnerships with hospitals and research institutions
- Growth in precision medicine applications
- International market penetration
Risk Factors
- High cash burn and negative ROIC
- Competitive landscape in health tech
- Regulatory hurdles in data privacy
Portfolio Diversification Insights
This watchlist spans healthcare, media, industrials, and biotechnology, offering broad sector allocation and risk mitigation. Healthcare stocks (Cencora, Cardinal Health, Supernus, SOPHiA GENETICS) provide defensive growth, while media (Fox, Warner Bros.) and industrials (Mueller) add cyclical upside. Abivax introduces high-growth biotech exposure, balancing the portfolio with both stability and innovation.
Market Timing & Entry Strategies
Investors may consider staggered entry points based on sector momentum and individual stock catalysts. Healthcare and industrial picks offer resilience during market volatility, while media and biotech stocks may benefit from event-driven surges. Monitoring earnings releases, regulatory updates, and macroeconomic trends can help refine entry timing for each position.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were chosen using ValueSense’s intrinsic value ratings, financial metrics, and sector diversification criteria, focusing on companies with strong growth potential and attractive valuations.
Q2: What's the best stock from this list?
Each stock offers unique strengths; for operational excellence, Mueller Industries (MLI) stands out, while Abivax (ABVX) shows exceptional growth potential. Selection depends on individual investment goals.
Q3: Should I buy all these stocks or diversify?
Diversification across sectors—healthcare, media, industrials, biotech—can help balance risk and capture varied growth opportunities, as reflected in this watchlist.
Q4: What are the biggest risks with these picks?
Risks include high debt levels, regulatory changes, competitive pressures, and sector-specific volatility. Each stock’s risk profile is detailed in its analysis section.
Q5: When is the best time to invest in these stocks?
Optimal timing depends on sector trends, company-specific catalysts, and market conditions. Monitoring earnings, regulatory updates, and macroeconomic signals can inform entry strategies.